Cisplatin Pfizer

Cisplatin Pfizer

cisplatin

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma

Marketer:

DKSH
Concise Prescribing Info
Contents
Cisplatin
Indications/Uses
Monotherapy or in combination w/ other chemotherapeutic agents for metastatic non-seminomatous germ cell carcinoma, advanced stage refractory ovarian & bladder carcinoma, refractory squamous cell head & neck carcinoma.
Dosage/Direction for Use
Adult & childn Monotherapy 50-100 mg/m2 as single IV infusion every 3-4 wk over 6-8 hr or 15-20 mg/m2 slow IV infusion daily for 5 days every 3-4 wk. Testicular cancer In combination w/ vinblastine, bleomycin, actinomycin D. Ovarian cancer In combination w/ cyclophosphamide, doxorubicin, hexamethylmelamine, 5-fluorouracil. Head & neck cancer In combination w/ bleomycin, methotrexate.
Contraindications
Hypersensitivity to cisplatin- or platinum-containing compd. Hearing disorders, bone marrow depression. Renal impairment. Pregnancy & lactation.
Special Precautions
Anaphylaxis-like reactions, family history of atopy. Discontinue use if severe nausea & vomiting occur. Cessation of treatment if peripheral neuropathy, postural hypotension, myasthenic syndromes, seizures & vision loss occur. Cumulative nephrotoxicity & ototoxicity; myelosuppression; Coombs' +ve haemolytic anaemia; hypomagnesemia & secondary hypocalcemia; CV toxicity. Monitor renal function (including GFR), BUN, serum creatinine & CrCl; electrolytes, auditory function, RBC, WBC & platelets, liver function & neurological status prior to initial therapy then before subsequent doses. Preexisting hepatic & renal dysfunction. Women of childbearing potential should use effective contraception. Not recommended during pregnancy & lactation.
Adverse Reactions
Nausea, vomiting; acute renal toxicity; mild bone marrow toxicity, anemia; anaphylactic & anaphylactic-like reactions; unilateral or bilateral tinnitus &/or hearing loss; peripheral & autonomic neuropathy, seizures, slurred speech, loss of taste & memory, CVA; retinal toxicity; CV abnormalities; venous thromboembolism, MI, thrombotic microangiopathy, cerebral arteritis; pulmonary toxicity; mild & transient serum AST & ALT elevations; mild alopecia; myalgia; spermatogenesis & azoospermia impairment; hypomagnesaemia, hypocalcaemia, hypokalaemia, renal tubular dysfunction, hyperuricemia, hyponatremia, syndrome of inappropriate antidiuretic hormone; pyrexia, local effects eg, phlebitis, cellulitis & skin necrosis.
Drug Interactions
Exacerbated nephrotoxic & ototoxic effects w/ aminoglycosides or loop diuretics. Black precipitate w/ Al. Concomitant use w/ live vaccines.
ATC Classification
L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Cisplatin Pfizer inj 1 mg/mL
Packing/Price
10 mL x 1's;10 mL x 5 × 1's;100 mL x 1's;50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in